8-K: Philip Morris International Announces Quarterly Dividend of $1.30 Per Share

Philip Morris International declared a regular quarterly dividend of $1.30 per common share, payable on April 9, 2024, to shareholders of record as of March 21, 2024.

Summary

• Philip Morris International (PMI) has announced a regular quarterly dividend of $1.30 per common share.
• The dividend is payable on April 9, 2024, to shareholders of record as of March 21, 2024.
• The ex-dividend date is March 20, 2024.
• PMI is focused on delivering a smoke-free future and is expanding its portfolio beyond tobacco and nicotine.
• The company has invested $12.5 billion since 2008 in developing and commercializing smoke-free products.
• PMI acquired Swedish Match in 2022, creating a global smoke-free champion with IQOS and ZYN brands.
• As of December 31, 2023, PMI's smoke-free products were available in 84 markets.
• Approximately 20.8 million adults have switched to IQOS and stopped smoking.
• Smoke-free products accounted for about 37% of PMI's total full-year 2023 net revenues.
• PMI is expanding into wellness and healthcare through its Vectura Fertin Pharma business.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the regular dividend announcement and the company's continued progress in transitioning to smoke-free products and expanding into new sectors.

Positives

• The company is committed to returning value to shareholders through regular dividends.
• PMI is making significant investments in smoke-free products.
• The company is successfully transitioning to a smoke-free future with a substantial portion of revenue coming from these products.
• PMI is expanding into new sectors like wellness and healthcare.

Risks

• The company faces the challenge of transitioning away from traditional tobacco products.
• The company's success depends on the continued adoption of smoke-free products by consumers.
• Regulatory approvals and market acceptance of new products are critical for future growth.

Future Outlook

PMI aims to continue its transition to a smoke-free future and expand into wellness and healthcare sectors.

Management Comments

• PMI is actively delivering a smoke-free future and evolving its portfolio for the long term.
• The company is focused on developing and commercializing innovative smoke-free products for adults who would otherwise continue to smoke.
• PMI aims to enhance life through the delivery of seamless health experiences.

Industry Context

The announcement reflects the broader trend in the tobacco industry towards reduced-risk products and diversification into new sectors like healthcare and wellness, as companies adapt to changing consumer preferences and regulatory pressures.

Comparison to Industry Standards

• PMI's investment of $12.5 billion in smoke-free products is a significant commitment compared to some competitors.
• The 37% revenue contribution from smoke-free products is a strong indicator of progress in the transition away from traditional cigarettes, which is a key focus for the industry.
• The acquisition of Swedish Match and the success of IQOS and ZYN brands position PMI as a leader in the smoke-free category, similar to how British American Tobacco is pushing its Vuse brand.
• PMI's expansion into wellness and healthcare through Vectura Fertin Pharma is a strategic move similar to other large tobacco companies exploring diversification.

Stakeholder Impact

• Shareholders will receive a regular quarterly dividend of $1.30 per share.
• Employees are part of a company that is investing in new technologies and markets.
• Customers are being offered a wider range of smoke-free products.
• Suppliers are part of a supply chain that is adapting to new product lines.
• Creditors are dealing with a company that is generating revenue from new product lines.

Next Steps

• The dividend will be paid on April 9, 2024.
• PMI will continue to focus on its smoke-free product strategy and expansion into wellness and healthcare.

Key Dates

Keywords

dividend, smoke-free products, IQOS, ZYN, tobacco, Philip Morris International, Swedish Match, wellness, healthcare